Reading Time: 6 minutes On the 8 September 2023, members of the Research Development team at the MND Association attended the 4th UCL Queen Square Motor Neuron Disease Centre International Symposium. Leading international researchers were invited to speak about key areas of MND research, with a focus on translational research. We listened to talks on early laboratory research and…
Reading Time: 6 minutes QurAlis, a biotechnology company focused on developing precision medicines for MND and other neurodegenerative diseases, has announced the opening of a clinical trial in the UK. This trial of a gene therapy, called QRL-201, is a phase 1 trial in people with MND and will test the therapy to determine whether it is safe and…
Reading Time: 7 minutes Clinical trials are vital in the hunt for effective treatments of motor neurone disease. They provide the evidence needed to determine whether a drug is safe and effective. In trials, participants are randomly assigned to receive either the treatment or a dummy drug, also known as a placebo. While this group is crucially important in…
Reading Time: 5 minutes The MND clinical trial landscape has grown vastly over the last decade and this has led to increased opportunities for people with MND to take part in research across the globe. Behind these trials, sit a large number of highly dedicated staff at each trial site who make sure the trial is set-up, recruiting and…
Reading Time: 6 minutes MND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains at the forefront of MND research. There have been over 140 clinical trials for MND over the last several decades and the majority of these have, unfortunately, not led to…
Reading Time: 5 minutes The current pace of clinical trials means that there are now more trials testing potential drugs for MND in the UK than ever before. One of these trials is MND-SMART which is designed to run for several years and give more people with the disease a chance to take part in a trial. The MND…
Reading Time: 6 minutes MND is a complex disease, and the causes are still not fully understood. Researchers all around the world are working tirelessly on different theories to try to understand more about what causes MND and how to treat it. One theory is that MND is caused by the activation of ancient viruses which are hidden within…
Reading Time: 5 minutes The pace of MND research continues to increase, with more clinical trials underway in the UK, over the last year, than ever before. Adding to this momentum, the clinical platform trial MAGNET (Multi-arm, Adaptive, Group-sequential trial NETwork)has just opened to recruitment in the UK.
Over the last several decades, there have been over 140 clinical trials for MND and unfortunately most of these have not led to effective treatments. More recently, clinical trial design has become more innovative, including the use of platform trials. MAGNET is a platform trial which aims to accelerate the development of new potential treatments for MND by testing multiple drugs simultaneously.
Reading Time: 4 minutes A new clinical trial, investigating Dazucorilant, for the treatment of MND is now open for recruitment in the UK. With this trial, there are now 6 clinical trials recruiting in the UK, further highlighting the current momentum in finding potential effective treatments for MND. People living with MND often show signs of over-active adrenal glands,…
Reading Time: 7 minutes On 25th April 2023 Tofersen (now known as Qalsody in the US), a treatment for SOD1 MND was approved by the Food and Drug Administration (FDA) in the United States. The FDA approval in the US is a welcome step forward in the fight against MND and further highlights the commitment and dedication of the…
